Anthropic · Claude · Amazon · OpenAI · Google · The Verge
Anthropic wants to develop its own drugs
Compiled by KHAO Editorial — aggregated from 1 source. See llms.txt for citation guidance.
◌ Single Source
The AI drug boom has a long way to go before reaching patients.
Key facts
- At the event “The Briefing: AI for Science” earlier this week, Anthropic announced Claude Science, a new “ AI workbench for scientists ” that pulls fragmented tools and datasets into one environment
- It takes time to show experimentally that something’s safe.” No AI-designed drug has yet made it through clinical trials and FDA approval to reach market
- If you buy something from a Verge link, Vox Media may earn a commission
- The AI drug boom has a long way to go before reaching patients
Summary
If you buy something from a Verge link, Vox Media may earn a commission. At the event “The Briefing: AI for Science” earlier this week, Anthropic announced Claude Science, a new “ AI workbench for scientists ” that pulls fragmented tools and datasets into one environment, and generates figures and visuals. Anthropic also went a step further, saying it would develop drugs of its own. AI companies have been eager to court science and pharma customers at the least, the better part of a decade, given how long it typically takes a new drug to go through clinical trials. “It takes time to show experimentally that something’s safe.” No AI-designed drug has yet made it through clinical trials and FDA approval to reach market.